EMEA-002452-PIP01-18

Key facts

Active substance
Marizomib
Therapeutic area
Oncology
Decision number
P/0403/2019
PIP number
EMEA-002452-PIP01-18
Pharmaceutical form(s)
Powder for solution for injection
Condition(s) / indication(s)
Treatment of malignant glial tumours
Route(s) of administration
Intravenous use
Contact for public enquiries
Celgene Europe B.V.

Tel. +41 327298500
E-mail: medinfo.emea@celgene.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating